MiR-223-3p in Cardiovascular Diseases: A Biomarker and Potential Therapeutic Target

Zhang, Mengwan; Shen, Yafei; Shi, Jing; Yu, Jian-Guang

doi:10.3389/fcvm.2020.610561

Cited by 34 publications

(27 citation statements)

References 204 publications

(299 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the specific expression of miRNA-223-3p, it can be used as a biomarker for a variety of diseases (33,34). Studies have confirmed that miRNA-223-3p can mediate the inflammatory response of cardiovascular diseases and has potential as a biomarker for the diagnosis and treatment of cardiovascular diseases (35). Recent studies have shown that the expression level of serum miRNA-223-3p can distinguish mild cognitive impairment, AD, and Parkinson's disease, suggesting that miRNA-223-3p can be used as a non-invasive biomarker for differential diagnosis and prognosis of these neurodegenerative diseases (36).…”

Section: Discussionmentioning

confidence: 99%

Exosomal miRNA-223-3p as potential biomarkers in patients with cerebral small vessel disease cognitive impairment

Zhao¹,

Sun

Li³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: Cerebrovascular disease is a common clinical illness. Many patients with cerebrovascular disease can be accompanied by cognitive impairment. The exosomal microRNA (miRNA)-223-3p is related to vascular endothelial injury, synaptic function, inflammatory response, and other mechanisms. In this study, we investigated the levels of plasma exosomal miRNA-223-3p in patients with cerebral small vessel disease (CSVD), in order to determine whether it could be used as a more accessible potential biomarker for the early diagnosis and treatment of CSVD. This study aimed to explore whether the development of cognitive impairment can be explained by differentially expressed miRNA-223-3p by detecting the level of miRNA-223-3p, which is abundant in peripheral blood exosomes related to cognitive impairment in CSVD. Methods:The three groups of participants included 40 patients with CSVD cognitive impairment (CSVDCI), 38 patients with CSVD, and 35 normal controls (NC). The real-time polymerase chain reaction (RT-PCR) was used to detect the expression level of blood exosomal miRNA-223-3p. In addition, we also studied the relationship between exosomal miRNA-223-3p and blood Hcy and C-reactive protein (CRP).Receiver-operating characteristic (ROC) curve analysis was used to evaluate the diagnostic efficacy of plasma exosomal miRNA-223-3p. Results:The expression of exosomal miRNA-223-3p in CSVD increased, and the expression of miRNA-223-3p increased significantly with the occurrence of cognitive impairment. Exosomal miRNA-223-3p was positively correlated with the expression levels of Hcy and CRP in the blood. Conclusions:The expression of plasma exosomal miRNA-223-3p is associated with the development of cognitive impairment in patients with CSVD. It may be involved in the pathogenesis of CSVD and cognitive impairment, and can be used as a sensitive predictive biomarker.

show abstract

Section: Discussionmentioning

confidence: 99%

Exosomal miRNA-223-3p as potential biomarkers in patients with cerebral small vessel disease cognitive impairment

Zhao¹,

Sun

Li³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“… 46 , 47 Additionally, recent reports recognized the detrimental role of miR-223-3p in autophagy process through suppressing NF-κB. 48 , 49 However, to the best of our knowledge, no data on miR-223-3p level in PCOS pancreas is available. Real-time PCR quantification revealed significant downregulation of miR-223-3p in the PCOS group compared with the normal control.…”

Section: Discussionmentioning

confidence: 99%

Nanocurcumin Modulates miR-223-3p and NF-κB Levels in the Pancreas of Rat Model of Polycystic Ovary Syndrome to Attenuate Autophagy Flare, Insulin Resistance and Improve ß Cell Mass

Abuelezz¹,

Shabana²,

Rashed³

et al. 2021

JEP

View full text Add to dashboard Cite

Purpose Polycystic ovary syndrome (PCOS) is a prevalent female endocrine disorder. 50–70% of PCOS patients suffer from glucose intolerance, insulin and β cell impairments. Updated studies reveal the crucial regulatory role of inflammation modulators in various diseases, by manipulating autophagy and oxidative stress. However, the data available about autophagy in PCOS pancreas, especially in relation to inflammation key players are little. This study investigated pancreatic autophagy status in PCOS rat model, with miR-223-3p and NF-κB levels as pivotal regulators of oxidative stress-autophagy axis, insulin, and β cell integrity. We then analyzed nanocurcumin effects as a putative anti-inflammatory nutraceutical on the disrupted parameters. Methods Nanocurcumin was characterized using transmission electron microscopy (TEM) and Fourier-transform IR (FT-IR) spectroscopy. Adult virgin Wistar rats were selected, and PCOS was induced using letrozole (1mg/kg). Nanocurcumin was ingested following letrozole. Sex hormones and insulin resistance were determined. miR-223-3p expression was determined using real-time PCR. Immunohistochemistry and Western blotting determined β cells, NF-κB, and autophagy markers p62 and LC3II. Results PCOS group showed significant disruptions in sex hormones and a double fold increase in glucose and insulin levels, exhibiting insulin resistance. Immunostaining confirmed around 46% deterioration of ß cell mass. Real-time PCR showed significant downregulation of miR-223-3p. Immunohistochemistry and Western blotting revealed a drastic upsurge of NF-κB, and autophagy markers p62 and LC3II, confirming bioinformatics target analysis. Interestingly, compared to PCOS group, nanocurcumin (200mg/kg) significantly upregulated miR-223-3p expression by 30%. It subsided NF-κB and autophagy eruption to restore ß cell mass and attenuate insulin resistance. Conclusion To the best of our knowledge, this study is the first to highlight the vital contribution of miR-223-3p and NF-κB levels in aggravating PCOS pancreatic autophagy and consequent impairments. It spots nanocurcumin potential as an inflammation and autophagy modulator, for possible better management of PCOS complications.

show abstract

“…These miRNA were shown to contribute to an anti-inflammatory phenotype, as demonstrated by increased expression of Arg1, Il10 and Mrc1 in LPS-stimulated macrophages and reduced endothelial cell response to VEGF (69). Similarly to miR-192, studies have shown miR-21, miR-146a and miR-223 to be increased in EVs isolated from patients with COPD or other chronic diseases, such as osteoporosis, CVD and diabetes (70)(71)(72)(73)(74)(75)(76)(77). Therefore, these EV miRNA may provide a common link and potential biomarker for accelerated ageing and age-related diseases.…”

Section: Evs As Immunomodulatory Factors In Ageingmentioning

confidence: 99%

The Role of Extracellular Vesicles as a Shared Disease Mechanism Contributing to Multimorbidity in Patients With COPD

et al. 2021

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide. Individuals with COPD typically experience a progressive, debilitating decline in lung function as well as systemic manifestations of the disease. Multimorbidity, is common in COPD patients and increases the risk of hospitalisation and mortality. Central to the genesis of multimorbidity in COPD patients is a self-perpetuating, abnormal immune and inflammatory response driven by factors including ageing, pollutant inhalation (including smoking) and infection. As many patients with COPD have multiple concurrent chronic conditions, which require an integrative management approach, there is a need to greater understand the shared disease mechanisms contributing to multimorbidity. The intercellular transfer of extracellular vesicles (EVs) has recently been proposed as an important method of local and distal cell-to-cell communication mediating both homeostatic and pathological conditions. EVs have been identified in many biological fluids and provide a stable capsule for the transfer of cargo including proteins, lipids and nucleic acids. Of these cargo, microRNAs (miRNAs), which are short 17-24 nucleotide non-coding RNA molecules, have been amongst the most extensively studied. There is evidence to support that miRNA are selectively packaged into EVs and can regulate recipient cell gene expression including major pathways involved in inflammation, apoptosis and fibrosis. Furthermore changes in EV cargo including miRNA have been reported in many chronic diseases and in response to risk factors including respiratory infections, noxious stimuli and ageing. In this review, we discuss the potential of EVs and EV-associated miRNA to modulate shared pathological processes in chronic diseases. Further delineating these may lead to the identification of novel biomarkers and therapeutic targets for patients with COPD and multimorbidities.

show abstract

MiR-223-3p in Cardiovascular Diseases: A Biomarker and Potential Therapeutic Target

Cited by 34 publications

References 204 publications

Exosomal miRNA-223-3p as potential biomarkers in patients with cerebral small vessel disease cognitive impairment

Exosomal miRNA-223-3p as potential biomarkers in patients with cerebral small vessel disease cognitive impairment

Nanocurcumin Modulates miR-223-3p and NF-κB Levels in the Pancreas of Rat Model of Polycystic Ovary Syndrome to Attenuate Autophagy Flare, Insulin Resistance and Improve ß Cell Mass

The Role of Extracellular Vesicles as a Shared Disease Mechanism Contributing to Multimorbidity in Patients With COPD

Contact Info

Product

Resources

About